AF
RIGL icon

Allworth Financial’s Rigel Pharmaceuticals RIGL Stock Holding History

Allworth Financial’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9K Buy
482
+273
+131% +$8.42K ﹤0.01% 3249
2026
Q1 		$5.65K Sell
209
-104
-33% -$3.5K ﹤0.01% 3889
2025
Q4 		$13.4K Buy
313
+102
+48% +$3.85K ﹤0.01% 3065
2025
Q3 		$5.98K Sell
211
-11
-5% -$329 ﹤0.01% 3449
2025
Q2 		$4.16K Hold
222
– – ﹤0.01% 3360
2025
Q1 		$4.23K Hold
222
– – ﹤0.01% 2860
2024
Q4 		$4.84K Buy
222
+82
+59% +$1.57K ﹤0.01% 2779
2024
Q3 		$2.27K Hold
140
– – ﹤0.01% 2913
2024
Q2 		$1.35K Sell
140
-29
-17% -$304 ﹤0.01% 3063
2024
Q1 		$2.51K Hold
169
– – ﹤0.01% 2729
2023
Q4 		$2.46K Buy
169
+29
+21% +$297 ﹤0.01% 2588
2023
Q3 		$1.51K Hold
140
– – ﹤0.01% 2674
2023
Q2 		$1.81K Hold
140
– – ﹤0.01% 2525
2023
Q1 		$1.85K Buy
+140
New +$2.22K ﹤0.01% 2435

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allworth Financial's RIGL Position: Q2 2026 in Review

Allworth Financial increased its Rigel Pharmaceuticals (RIGL) stake by 131% in Q2 2026, buying an estimated $8.42K and bringing the position to 482 shares worth $18.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3249.

Allworth Financial first reported a position in RIGL in Q1 2023 and has held it in 14 quarters since. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Allworth Financial held 482 shares of Rigel Pharmaceuticals worth $18.9K as of Q2 2026.
  • Allworth Financial bought 273 Rigel Pharmaceuticals shares in Q2 2026, an estimated $8.42K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3249 holding.
  • Allworth Financial first reported a position in Rigel Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.